Piperazinyl pyrimidine derivatives as potent γ-secretase modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1269-1271

  Rivkin, Alexey ^a   Ahearn, Sean P ^a   Chichetti, Stephanie M ^a   Kim, Yoona R ^a   Li, Chaomin ^a   Rosenau, Andrew ^a   Kattar, Sam D ^a   Jung, Joon ^a   Shah, Sanjiv ^a   Hughes, Bethany L ^a   Crispino, Jamie L ^a   Middleton, Richard E ^a   Szewczak, Alexander A ^a   Munoz, Benito ^a   Shearman, Mark S ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alzheimer's disease; Secretase modulators

Indexed keywords

GAMMA SECRETASE; NOTCH RECEPTOR; PIPERAZINYL PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (40-42); PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE; SECRETASE;

ARTICLE; BIOLOGICAL ACTIVITY; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; IN VITRO STUDY; PROTEIN CLEAVAGE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPARATIVE STUDY; HELA CELL LINE; HUMAN; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; CELL LINE, TUMOR; HELA CELLS; HUMANS; PEPTIDE FRAGMENTS; PIPERAZINES; PYRIMIDINES;

EID: 74049093168     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.101     Document Type: Article

References (24)

1. Selkoe D. Physiol. Rev. 81 (2001) 741
2. Hardy J.A., and Higgins G.A. Science 256 (1992) 184
3. Golde T.E. J. Clin. Invest. 111 (2003) 1
4. Herbert L.E., Beckett L.A., Scherr P.A., and Evans D.A. Alzheimer Dis. Assoc. Disord. 15 (2001) 169
5. Griffiths H.H., Morten I., and Hooper N.M. Expert Opin. Ther. 12 (2008) 704
6. Cummings J.L. N. Eng. J. Med. 351 (2004) 56
7. Dickson D.W. J. Neuropathol. Exp. Neurol. 56 (1997) 321
8. Hardy J., and Selkoe D.J. Science 297 (2002) 353
9. Imbimbo B.P. Curr. Top. Med. Chem. 8 (2008) 54
10. Maillard I., Adler S.H., and Pear W.S. Immunity 19 (2003) 781
11. (b). Stanger B.Z., Datar R., Murtaught L.C., and Melton D.A. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 12443
12. Behr D. Curr. Top. Med. Chem. 8 (2008) 34
13. In't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., Van Duijn C.M., Stijnen T., Breteler M.M.B., and Stricker B.H.C. N. Eng. J. Med. 345 (2001) 1515
14. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Butler T., Kang D.E., Marquez-Sterling N., Golde T.E., and Koo E.H. Nature 414 (2001) 212
15. Lim G.P., Yang F., Chu T., Chem P., Beech W., Teter B., Tran T., Ubeda O., Hsaio Ahse K., Reautschy S.A., and Cole G.M. J. Neurosci. 20 (2000) 5709
16. Peretto I., and La Porta E. Curr. Top. Med. Chem. 8 (2008) 38
17. Pissarnitski D. Curr. Opin. Drug Disc. Dev. 10 (2007) 392
18. Blurton, P.; Fletcher, S.; Teall, M.; Harrison, T.; Munoz, B.; Rivkin, A.; Hamblett, C.; Siliphaivanh, P.; Otte, K. WO 099210, 2008.
19. 50 measurements for Aβ40 and Aβ42 were determined using electrochemiluminescent detection of peptides secreted by SH-SY5Y cells stably overexpressing the β-APP C-terminal fragment SPA4CT. Consistent with the profiles of γ-secretase modulators, total Aβ peptide levels were constant. Best J.D., Jay M.T., Otu F., Ma J., Nadin A., Ellis S., Lewis H.D., Pattison C., Reilly M., Harrison T., Shearman M.S., Williamson T.L., and Atack J.R.J. Pharm. Exp. Ther. 313 (2005) 902
20. Clarke E.E., and Shearman M.S. J. Neurosci. Methods 102 (2000) 61
21. Dyrks T., Dyrks E., Monning U., Urmoneit B., Turner J., and Beyreuther K. FEBS Lett. 335 (1993) 89
22. Compound 29 was prepared using methods reported by. Li C., and Rosenau A. Tetrahedron Lett. (2009) 5888
23. Conformational analysis was performed with the implicit Generalized-Born solvent model with 8 kcal/mol energy cutoff. Clustering of conformers based on the atomic RMS dissimilarity was used to generate the 10 most diverse representative conformers. Two of the most diverse conformers for 1 and 2 are shown in Figure 2.
24. HeLa cells were made to co-express nonfunctional halves of luciferase, one fused to NotchΔE and the other to RBP-Jκ. γ-Secretase mediated cleavage of NotchΔE results in release of Notch intracellular domain (NICD)/N-terminal luciferase, which translocates to the nucleus and binds the RBP-Jκ/C-terminal luciferase to form a functional luciferase enzyme. This split-luciferase complementation system is used to detect NICD levels by measuring total luminescence upon addition of luciferin to lysed cells. Paulmurugan R., and Gambhir S.S. Anal. Chem. 77 (2005) 1295